Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine

Does the pneumococcal polysaccharide vaccine prevent heart attacks and strokes?In this randomized clinical trial of 4725 adults with increased cardiovascular risk, there was no significant difference in fatal and nonfatal acute coronary syndrome and ischemic stroke over a mean follow-up period of 7 years, although the event rate was lower than expected leading to low power.Study results revealed that the cardioprotective effect hypothesized from earlier animal and human observational studies was not replicated in a large-scale randomized clinical trial, using data linkage for virtual follow-up.

Corresponding Author: John Attia, MD, PhD, Centre for Clinical Epidemiology and Biostatistics, The University of Newcastle–Callaghan Campus, 150 University Dr, Callaghan, NSW 2308, Australia (john.attia@newcastle.edu.au).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.